Therapeutic targeting of PRAME with (mTCR)CAR T cells in acute myeloid leukemia

Preferentially Expressed Antigen in Melanoma (PRAME), a cancer-testis antigen, provides an ideal target for immunotherapy in acute myeloid leukemia (AML). We have shown expression of PRAME in a significant subset of childhood and adult AML and lack of expression in normal hematopoiesis. Although an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirkey, Danielle C., Loeb, Anisha M., Castro, Sommer, McKay, Cyd Nourigat, Perkins, LaKeisha, Pardo, Laura, Leonti, Amanda R., Tang, Thao T., Loken, Michael R., Brodersen, Lisa Eidenschink, Loeb, Keith R., Scheinberg, David A., Le, Quy, Meshinchi, Soheil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111362/
https://www.ncbi.nlm.nih.gov/pubmed/35984639
http://dx.doi.org/10.1182/bloodadvances.2022008304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111362/
https://www.ncbi.nlm.nih.gov/pubmed/35984639
http://dx.doi.org/10.1182/bloodadvances.2022008304

Ejemplares similares